Robert M. Jones;Daniel J. Buzard;Thomas O. Schrader;Michelle Kasem;Benjamin R. Johnson;Scott Stirn;Tawfik Gharbaoui
发明人:
Robert M. Jones,Daniel J. Buzard,Tawfik Gharbaoui,Benjamin R. Johnson,Michelle Kasem,Thomas O. Schrader,Scott Stirn
申请号：
US13581846
公开号：
US20120329848A1
申请日:
2011.03.02
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions eases characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
